Hidradenitis suppurativa (HS) is a chronic skin disease that predominantly affects the skin of the intertriginous area through an inflammatory process and results in recurrent nodules, abscesses, sinuses, fistulas, and scarring.
1,2 Because the precise description of HS may provide a challenge, considerable efforts have been made to formulate diagnostic criteria and validate clinical descriptive terms for the lesions occurring in patients with HS.
3,4 In addition, an international initiative (HS core outcomes set international collaboration) has started to develop a list of mandatory outcomes that should be measured in clinical trials on the treatment of HS.
5 However, the variation in clinical appearance and the variability in response to a wide range of proposed treatments underline the importance of an accurate disease severity assessment tool.
1,6